I agree. Having listened carefully to the conference call, the 'signal' appears to be limited to CX717. One can see proceeding with testing in Alzheimer's with PET scanning and ramping up as many potent low-impacts as possible while still proceeding with CX717 on the histological trail. The worst case scenario here might be the end of CX717 from the practical standpoint. We also know the histological issue was not spurious, not an anomaly, but might be related to an ultra-high dose administration. Although I'm dissapointed, I greatly appreciate Dr. Stoll's presentation for its honesty and exhaustion.
Market Data 
Markets 
AI
